NGS Sample Preparation Market by Product Type (Amplification Kits, Fragmentation And Size Selection, Library Prep Kits), Technology (Bead Based, Enzyme Based, Microfluidics), Workflow Step, Application, End User - Global Forecast 2025-2032
Description
The NGS Sample Preparation Market was valued at USD 2.78 billion in 2024 and is projected to grow to USD 3.24 billion in 2025, with a CAGR of 16.52%, reaching USD 9.45 billion by 2032.
An authoritative introduction outlining how advances in chemistry, automation, and regulatory demands are redefining sample preparation workflows and laboratory priorities
Next-generation sequencing (NGS) sample preparation stands at the intersection of technological maturation and growing demand from clinical, research, and industrial laboratories. Advances in sequencing throughput, the diversification of applications such as transcriptomics, metagenomics, and epigenetics, and the push toward decentralization of genomic assays have placed enormous emphasis on upstream processes that determine data quality, reproducibility, and cost efficiency. Sample preparation encompasses a complex suite of molecular biology operations-fragmentation, enrichment, amplification, library preparation, and quality control-each of which contributes to the fidelity of downstream sequencing and the interpretability of results.
Over the last several years, instrument makers and reagent suppliers have moved beyond incremental improvements to integrate automation, chemistry innovations, and modular workflows that respond to both high-throughput clinical labs and low-input or degraded sample contexts. Concurrently, regulatory scrutiny and clinical validation requirements have elevated demands on traceability and robust QC metrics, prompting closer convergence between sample prep design and laboratory information management systems. This introduction frames the core technological, operational, and market forces that determine which sample preparation approaches will gain traction and why laboratories and vendors must adapt rapidly to meet evolving scientific and commercial imperatives.
How converging innovations in chemistry, microfluidics, and integrated workflows are accelerating practical adoption and diversifying sequencing applications
The landscape for NGS sample preparation is undergoing transformative shifts driven by converging forces across technology, workflow integration, and application diversification. Chemistry innovations, including transposase-mediated fragmentation and enzymatic barcoding, are reducing hands-on time and improving uniformity for low-input and degraded samples, which in turn expands the practical use cases for sequencing in clinical diagnostics and field-deployable studies. Parallel to these chemistry advances, microfluidics and droplet-based systems have matured, enabling miniaturized reactions that lower reagent consumption and increase parallelization, while also supporting single-cell and ultra-sensitive RNA applications.
Workflow integration is another major vector of change. Vendors increasingly offer end-to-end solutions that knit together extraction, library preparation, and quantification within harmonized protocols and automation platforms, reducing variability and accelerating time-to-result. This integration supports new commercial models where reagent makers partner with instrument manufacturers and software providers to deliver validated bundles for specific applications such as oncology panels or inherited disease testing. Finally, the rise of novel applications-expanded metagenomics profiling, epigenetic assays, and high-resolution transcriptomics-has driven demand for flexible, modular kits that can be adapted to different input types and sequencing objectives. Taken together, these shifts are reshaping product roadmaps, procurement strategies, and laboratory staffing models as organizations balance accuracy, throughput, and cost.
How 2025 tariff shifts are reshaping supplier strategies and laboratory procurement priorities by elevating supply chain resilience and regional manufacturing focus
The cumulative impact of trade policy changes and tariff adjustments in 2025 has introduced new complexity into procurement and supply chain planning for reagents, consumables, and instruments used in NGS sample preparation. Manufacturers that rely on globalized production networks have had to reassess sourcing strategies, balancing the need to maintain consistent quality against the pressures of increased duties and shipping variability. For many organizations, higher input costs and longer lead times have elevated the importance of supply chain resilience, driving a strategic pivot toward multi-sourcing, localized inventory buffers, and deeper vendor partnerships that emphasize contractual protections and preferred pricing structures.
These tariff dynamics also influence product design choices: suppliers are exploring formulation adjustments that reduce dependency on tariff-exposed components, consolidating multi-part kits to limit cross-border complexity, and accelerating the certification of regional manufacturing to reduce exposure to import duties. On the laboratory side, procurement teams are revisiting procurement cadences and inventory management systems to mitigate operational risk, while R&D groups are prioritizing assay robustness to accommodate potential substitutions in consumables. The net effect is a more cautious, resilience-oriented market posture that privileges validated supply continuity and adaptable workflows.
Comprehensive segmentation analysis revealing how product types, applications, technologies, workflows, and end users define differentiated requirements and market dynamics
Understanding the segmentation of sample preparation is essential for designing products and go-to-market strategies that align with user needs across diverse workflows. By product type, the space spans Amplification Kits, Fragmentation and Size Selection, Library Prep Kits, and Target Enrichment Kits; within amplification, conventional PCR, digital PCR, and qPCR variants coexist alongside rolling circle approaches such as padlock probe-based and Phi29-based methods. Fragmentation strategies differentiate enzymatic endonuclease and transposase modalities from mechanical approaches exemplified by established instruments. Library preparation divides into RNA-focused preparations-mRNA, small RNA, and total RNA-targeted library kits for inherited disease and oncology panels, and whole genome libraries including PCR-free and standard WGS kits. Target enrichment strategies further split into amplicon enrichment, where multiplex and singleplex PCR approaches dominate, and hybridization capture methods offered in array-based and solution-based formats.
Application-driven segmentation reveals overlapping but distinct performance expectations. Epigenetics workflows require bisulfite or ChIP sequencing compatibility and robust handling of chemically modified templates. Metagenomics workflows seek methods optimized for 16S rRNA profiling or shotgun approaches, with rigorous contamination control. RNA sequencing users expect flexible library prep that accommodates miRNA, mRNA, and total RNA profiling. Targeted sequencing applications prioritize panels for inherited disease, oncology, and pharmacogenomics, each demanding specific sensitivity and coverage characteristics. Technology segmentation highlights bead-based solutions-magnetic and solid phase-enzyme-based chemistries including ligases and transposases, as well as microfluidic platforms and PCR-based modalities. Workflow step segmentation clarifies where value is created: amplification, enrichment, fragmentation, library prep, and quantification and QC each require distinct quality controls and automation options. Finally, end users range from academic and government laboratories to contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, each bringing unique throughput, validation, and procurement requirements that influence kit design, support services, and commercialization pathways.
Regional intelligence demonstrating how differing clinical priorities, regulatory frameworks, and manufacturing capabilities shape adoption and commercialization strategies
Regional dynamics exert a profound influence on how sample preparation strategies are adopted, supported, and commercialized. In the Americas, a strong emphasis on clinical translation and investment in sequencing infrastructure has accelerated demand for validated kits and automation platforms, while a robust biotech and pharma sector drives demand for specialized panels, high-throughput library prep, and integrated QC solutions. In addition, regulatory pathways and reimbursement considerations in healthcare systems shape productization timelines and the level of documentation required for clinical adoption. Cross-border trade within the region also affects logistics and distribution models, pushing vendors toward localized stocking and regional technical support hubs.
The Europe, Middle East & Africa region presents a heterogeneous landscape where centralized academic centers coexist with emerging diagnostic networks. Collaborative research consortia and pan-European initiatives promote standardization and interoperability, influencing vendor requirements for harmonized protocols and data traceability. Regulatory diversity and varied healthcare funding models mean that product strategy must be granular and adaptable. In Asia-Pacific, rapid capacity expansion, strong public investment in genomics, and a burgeoning molecular diagnostics market have created a fertile environment for both high-throughput platforms and modular, cost-efficient kits tailored to local needs. Regional manufacturing capability and government incentives often accelerate localization of production, while diverse sample types and application priorities encourage suppliers to offer flexible kit formats and localized technical support.
Competitive dynamics and partnership strategies that determine vendor differentiation through validated kits, automation, and integrated informatics support
A nuanced view of the competitive landscape highlights how leading reagent suppliers, instrument manufacturers, and software providers position themselves through product breadth, integrated workflows, and service capabilities. Established reagent companies focus on expanding validated kits across application verticals, emphasizing assay robustness, lot-to-lot consistency, and regulatory documentation to serve clinical and high-throughput customers. Instrument manufacturers differentiate through automation, throughput scalability, and the ability to harmonize sample preparation steps with downstream sequencing, thereby reducing hands-on time and error rates. Software and informatics players complement this ecosystem by integrating sample tracking, QC analytics, and protocol standardization, enabling customers to operationalize complex workflows at scale.
Strategic partnerships and co-development agreements have become increasingly common as companies seek to offer bundled solutions that accelerate customer adoption. Some firms focus on vertical integration, offering end-to-end platforms with native consumables and validated protocols, while others emphasize modularity to attract laboratories that value flexibility and the ability to mix-and-match best-of-breed components. Competitive advantage increasingly derives from the ability to support customers with technical training, global logistics proficiency, and responsive regulatory support, particularly for organizations pursuing clinical validation. The interplay of these capabilities determines procurement decisions and shapes the routes by which innovation enters the market.
High-impact recommendations for vendors and laboratories to accelerate adoption and strengthen resilience through modular design, automation, and supply chain diversification
Industry leaders should pursue a set of targeted, actionable strategies to capture value in the evolving sample preparation landscape. Prioritize the development of modular, application-specific kits that minimize hands-on time while maximizing compatibility with a broad range of input qualities and instrumentation. Investing in automation-ready protocols and validated workflows will lower barriers for clinical and high-throughput customers. Simultaneously, cultivate supply chain resilience by diversifying manufacturing footprints and qualifying multiple suppliers for critical inputs, thereby reducing exposure to tariffs and logistic disruptions.
Commercially, vendors should deepen engagements with key end-user segments by offering training, local technical support, and documentation tailored to regulatory requirements. Forge partnerships that enable bundled offerings combining consumables, automation platforms, and informatics to create sticky solutions with higher lifetime value. For procurement and laboratory leaders, implement robust vendor qualification processes and scenario-driven inventory planning that account for regional trade dynamics and lead-time variability. Finally, commit to continuous improvement in QC and traceability, adopting standardized metrics and digital QA tools to enhance reproducibility and meet the rigorous standards required for clinical and regulatory acceptance.
A transparent, evidence-based research methodology blending primary interviews, protocol validation reviews, and rigorous secondary analysis to ground conclusions in operational reality
The research underpinning this analysis combined primary stakeholder interviews, protocol validation reviews, and secondary literature synthesis to ensure a balanced and actionable perspective. Primary engagements included conversations with laboratory directors, procurement officers, R&D leaders, and product managers across academic, diagnostic, and commercial settings to surface real-world priorities and constraints. Protocol validation reviews assessed published methods and vendor documentation to compare performance attributes such as input requirements, hands-on time, and compatibility with downstream analytics. Secondary research incorporated peer-reviewed literature, white papers, regulatory guidance documents, and vendor technical notes to contextualize technological trends and regulatory expectations.
Analytical rigor was maintained by triangulating qualitative insights with documented use cases and public technical specifications. The methodology emphasized transparency in assumptions and explicit articulation of evidence sources for each thematic conclusion. This approach enabled the identification of emergent patterns-such as the shift toward automation-ready chemistries and the influence of regional manufacturing policies-while ensuring that recommendations are grounded in observable operational realities rather than speculative forecasts. Wherever possible, the research concentrated on reproducible factors like protocol complexity, supply chain configuration, and validation burden that directly inform procurement and product development decisions.
A concluding synthesis emphasizing why robust, automation-ready, and regionally resilient sample preparation strategies will determine sequencing success across applications
In conclusion, sample preparation is increasingly the strategic fulcrum for deriving reliable, cost-effective sequencing results and enabling broader deployment of NGS across clinical, research, and industrial domains. The technical innovations in chemistry and microfluidics, coupled with stronger demands for validated, automation-ready workflows, are shifting competitive advantage toward suppliers that can deliver harmonized solutions and robust support ecosystems. At the same time, trade policy shifts and regional manufacturing dynamics compel both vendors and laboratories to prioritize resilience in supply chains and flexibility in procurement.
Moving forward, organizations that align product development with the nuanced needs of different applications and end-user segments-while investing in automation compatibility, QC standardization, and regional supply strategies-will be best positioned to capture the opportunity presented by expanding NGS use cases. For laboratory leaders, the task is to integrate these technological and commercial considerations into procurement, validation, and staffing plans so that sample preparation becomes an enabler rather than a bottleneck for sequencing-driven insights.
Note: PDF & Excel + Online Access - 1 Year
An authoritative introduction outlining how advances in chemistry, automation, and regulatory demands are redefining sample preparation workflows and laboratory priorities
Next-generation sequencing (NGS) sample preparation stands at the intersection of technological maturation and growing demand from clinical, research, and industrial laboratories. Advances in sequencing throughput, the diversification of applications such as transcriptomics, metagenomics, and epigenetics, and the push toward decentralization of genomic assays have placed enormous emphasis on upstream processes that determine data quality, reproducibility, and cost efficiency. Sample preparation encompasses a complex suite of molecular biology operations-fragmentation, enrichment, amplification, library preparation, and quality control-each of which contributes to the fidelity of downstream sequencing and the interpretability of results.
Over the last several years, instrument makers and reagent suppliers have moved beyond incremental improvements to integrate automation, chemistry innovations, and modular workflows that respond to both high-throughput clinical labs and low-input or degraded sample contexts. Concurrently, regulatory scrutiny and clinical validation requirements have elevated demands on traceability and robust QC metrics, prompting closer convergence between sample prep design and laboratory information management systems. This introduction frames the core technological, operational, and market forces that determine which sample preparation approaches will gain traction and why laboratories and vendors must adapt rapidly to meet evolving scientific and commercial imperatives.
How converging innovations in chemistry, microfluidics, and integrated workflows are accelerating practical adoption and diversifying sequencing applications
The landscape for NGS sample preparation is undergoing transformative shifts driven by converging forces across technology, workflow integration, and application diversification. Chemistry innovations, including transposase-mediated fragmentation and enzymatic barcoding, are reducing hands-on time and improving uniformity for low-input and degraded samples, which in turn expands the practical use cases for sequencing in clinical diagnostics and field-deployable studies. Parallel to these chemistry advances, microfluidics and droplet-based systems have matured, enabling miniaturized reactions that lower reagent consumption and increase parallelization, while also supporting single-cell and ultra-sensitive RNA applications.
Workflow integration is another major vector of change. Vendors increasingly offer end-to-end solutions that knit together extraction, library preparation, and quantification within harmonized protocols and automation platforms, reducing variability and accelerating time-to-result. This integration supports new commercial models where reagent makers partner with instrument manufacturers and software providers to deliver validated bundles for specific applications such as oncology panels or inherited disease testing. Finally, the rise of novel applications-expanded metagenomics profiling, epigenetic assays, and high-resolution transcriptomics-has driven demand for flexible, modular kits that can be adapted to different input types and sequencing objectives. Taken together, these shifts are reshaping product roadmaps, procurement strategies, and laboratory staffing models as organizations balance accuracy, throughput, and cost.
How 2025 tariff shifts are reshaping supplier strategies and laboratory procurement priorities by elevating supply chain resilience and regional manufacturing focus
The cumulative impact of trade policy changes and tariff adjustments in 2025 has introduced new complexity into procurement and supply chain planning for reagents, consumables, and instruments used in NGS sample preparation. Manufacturers that rely on globalized production networks have had to reassess sourcing strategies, balancing the need to maintain consistent quality against the pressures of increased duties and shipping variability. For many organizations, higher input costs and longer lead times have elevated the importance of supply chain resilience, driving a strategic pivot toward multi-sourcing, localized inventory buffers, and deeper vendor partnerships that emphasize contractual protections and preferred pricing structures.
These tariff dynamics also influence product design choices: suppliers are exploring formulation adjustments that reduce dependency on tariff-exposed components, consolidating multi-part kits to limit cross-border complexity, and accelerating the certification of regional manufacturing to reduce exposure to import duties. On the laboratory side, procurement teams are revisiting procurement cadences and inventory management systems to mitigate operational risk, while R&D groups are prioritizing assay robustness to accommodate potential substitutions in consumables. The net effect is a more cautious, resilience-oriented market posture that privileges validated supply continuity and adaptable workflows.
Comprehensive segmentation analysis revealing how product types, applications, technologies, workflows, and end users define differentiated requirements and market dynamics
Understanding the segmentation of sample preparation is essential for designing products and go-to-market strategies that align with user needs across diverse workflows. By product type, the space spans Amplification Kits, Fragmentation and Size Selection, Library Prep Kits, and Target Enrichment Kits; within amplification, conventional PCR, digital PCR, and qPCR variants coexist alongside rolling circle approaches such as padlock probe-based and Phi29-based methods. Fragmentation strategies differentiate enzymatic endonuclease and transposase modalities from mechanical approaches exemplified by established instruments. Library preparation divides into RNA-focused preparations-mRNA, small RNA, and total RNA-targeted library kits for inherited disease and oncology panels, and whole genome libraries including PCR-free and standard WGS kits. Target enrichment strategies further split into amplicon enrichment, where multiplex and singleplex PCR approaches dominate, and hybridization capture methods offered in array-based and solution-based formats.
Application-driven segmentation reveals overlapping but distinct performance expectations. Epigenetics workflows require bisulfite or ChIP sequencing compatibility and robust handling of chemically modified templates. Metagenomics workflows seek methods optimized for 16S rRNA profiling or shotgun approaches, with rigorous contamination control. RNA sequencing users expect flexible library prep that accommodates miRNA, mRNA, and total RNA profiling. Targeted sequencing applications prioritize panels for inherited disease, oncology, and pharmacogenomics, each demanding specific sensitivity and coverage characteristics. Technology segmentation highlights bead-based solutions-magnetic and solid phase-enzyme-based chemistries including ligases and transposases, as well as microfluidic platforms and PCR-based modalities. Workflow step segmentation clarifies where value is created: amplification, enrichment, fragmentation, library prep, and quantification and QC each require distinct quality controls and automation options. Finally, end users range from academic and government laboratories to contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, each bringing unique throughput, validation, and procurement requirements that influence kit design, support services, and commercialization pathways.
Regional intelligence demonstrating how differing clinical priorities, regulatory frameworks, and manufacturing capabilities shape adoption and commercialization strategies
Regional dynamics exert a profound influence on how sample preparation strategies are adopted, supported, and commercialized. In the Americas, a strong emphasis on clinical translation and investment in sequencing infrastructure has accelerated demand for validated kits and automation platforms, while a robust biotech and pharma sector drives demand for specialized panels, high-throughput library prep, and integrated QC solutions. In addition, regulatory pathways and reimbursement considerations in healthcare systems shape productization timelines and the level of documentation required for clinical adoption. Cross-border trade within the region also affects logistics and distribution models, pushing vendors toward localized stocking and regional technical support hubs.
The Europe, Middle East & Africa region presents a heterogeneous landscape where centralized academic centers coexist with emerging diagnostic networks. Collaborative research consortia and pan-European initiatives promote standardization and interoperability, influencing vendor requirements for harmonized protocols and data traceability. Regulatory diversity and varied healthcare funding models mean that product strategy must be granular and adaptable. In Asia-Pacific, rapid capacity expansion, strong public investment in genomics, and a burgeoning molecular diagnostics market have created a fertile environment for both high-throughput platforms and modular, cost-efficient kits tailored to local needs. Regional manufacturing capability and government incentives often accelerate localization of production, while diverse sample types and application priorities encourage suppliers to offer flexible kit formats and localized technical support.
Competitive dynamics and partnership strategies that determine vendor differentiation through validated kits, automation, and integrated informatics support
A nuanced view of the competitive landscape highlights how leading reagent suppliers, instrument manufacturers, and software providers position themselves through product breadth, integrated workflows, and service capabilities. Established reagent companies focus on expanding validated kits across application verticals, emphasizing assay robustness, lot-to-lot consistency, and regulatory documentation to serve clinical and high-throughput customers. Instrument manufacturers differentiate through automation, throughput scalability, and the ability to harmonize sample preparation steps with downstream sequencing, thereby reducing hands-on time and error rates. Software and informatics players complement this ecosystem by integrating sample tracking, QC analytics, and protocol standardization, enabling customers to operationalize complex workflows at scale.
Strategic partnerships and co-development agreements have become increasingly common as companies seek to offer bundled solutions that accelerate customer adoption. Some firms focus on vertical integration, offering end-to-end platforms with native consumables and validated protocols, while others emphasize modularity to attract laboratories that value flexibility and the ability to mix-and-match best-of-breed components. Competitive advantage increasingly derives from the ability to support customers with technical training, global logistics proficiency, and responsive regulatory support, particularly for organizations pursuing clinical validation. The interplay of these capabilities determines procurement decisions and shapes the routes by which innovation enters the market.
High-impact recommendations for vendors and laboratories to accelerate adoption and strengthen resilience through modular design, automation, and supply chain diversification
Industry leaders should pursue a set of targeted, actionable strategies to capture value in the evolving sample preparation landscape. Prioritize the development of modular, application-specific kits that minimize hands-on time while maximizing compatibility with a broad range of input qualities and instrumentation. Investing in automation-ready protocols and validated workflows will lower barriers for clinical and high-throughput customers. Simultaneously, cultivate supply chain resilience by diversifying manufacturing footprints and qualifying multiple suppliers for critical inputs, thereby reducing exposure to tariffs and logistic disruptions.
Commercially, vendors should deepen engagements with key end-user segments by offering training, local technical support, and documentation tailored to regulatory requirements. Forge partnerships that enable bundled offerings combining consumables, automation platforms, and informatics to create sticky solutions with higher lifetime value. For procurement and laboratory leaders, implement robust vendor qualification processes and scenario-driven inventory planning that account for regional trade dynamics and lead-time variability. Finally, commit to continuous improvement in QC and traceability, adopting standardized metrics and digital QA tools to enhance reproducibility and meet the rigorous standards required for clinical and regulatory acceptance.
A transparent, evidence-based research methodology blending primary interviews, protocol validation reviews, and rigorous secondary analysis to ground conclusions in operational reality
The research underpinning this analysis combined primary stakeholder interviews, protocol validation reviews, and secondary literature synthesis to ensure a balanced and actionable perspective. Primary engagements included conversations with laboratory directors, procurement officers, R&D leaders, and product managers across academic, diagnostic, and commercial settings to surface real-world priorities and constraints. Protocol validation reviews assessed published methods and vendor documentation to compare performance attributes such as input requirements, hands-on time, and compatibility with downstream analytics. Secondary research incorporated peer-reviewed literature, white papers, regulatory guidance documents, and vendor technical notes to contextualize technological trends and regulatory expectations.
Analytical rigor was maintained by triangulating qualitative insights with documented use cases and public technical specifications. The methodology emphasized transparency in assumptions and explicit articulation of evidence sources for each thematic conclusion. This approach enabled the identification of emergent patterns-such as the shift toward automation-ready chemistries and the influence of regional manufacturing policies-while ensuring that recommendations are grounded in observable operational realities rather than speculative forecasts. Wherever possible, the research concentrated on reproducible factors like protocol complexity, supply chain configuration, and validation burden that directly inform procurement and product development decisions.
A concluding synthesis emphasizing why robust, automation-ready, and regionally resilient sample preparation strategies will determine sequencing success across applications
In conclusion, sample preparation is increasingly the strategic fulcrum for deriving reliable, cost-effective sequencing results and enabling broader deployment of NGS across clinical, research, and industrial domains. The technical innovations in chemistry and microfluidics, coupled with stronger demands for validated, automation-ready workflows, are shifting competitive advantage toward suppliers that can deliver harmonized solutions and robust support ecosystems. At the same time, trade policy shifts and regional manufacturing dynamics compel both vendors and laboratories to prioritize resilience in supply chains and flexibility in procurement.
Moving forward, organizations that align product development with the nuanced needs of different applications and end-user segments-while investing in automation compatibility, QC standardization, and regional supply strategies-will be best positioned to capture the opportunity presented by expanding NGS use cases. For laboratory leaders, the task is to integrate these technological and commercial considerations into procurement, validation, and staffing plans so that sample preparation becomes an enabler rather than a bottleneck for sequencing-driven insights.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of microfluidic platforms for automated single-cell NGS library preparation to enhance throughput and reduce reagent usage
- 5.2. Adoption of enzymatic fragmentation kits for streamlined DNA shearing and improved sequencing uniformity in NGS workflows
- 5.3. Development of magnetic bead–based cleanup systems for high-throughput, scalable NGS library purification and precise size selection
- 5.4. Implementation of robotics-driven end-to-end NGS sample prep solutions to minimize manual error and accelerate turnaround times
- 5.5. Emergence of barcoded transposase-based tagmentation methods for cost-effective multiplexed NGS library construction
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. NGS Sample Preparation Market, by Product Type
- 8.1. Amplification Kits
- 8.1.1. Pcr Kits
- 8.1.1.1. Conventional Pcr Kits
- 8.1.1.2. Digital Pcr Kits
- 8.1.1.3. Qpcr Kits
- 8.1.2. Rolling Circle Amplification
- 8.1.2.1. Padlock Probe Based
- 8.1.2.2. Phi29 Based
- 8.2. Fragmentation And Size Selection
- 8.2.1. Enzymatic Fragmentation
- 8.2.1.1. Endonuclease Based
- 8.2.1.2. Transposase Based
- 8.2.2. Mechanical Fragmentation
- 8.2.2.1. Bioruptor
- 8.2.2.2. Covaris
- 8.3. Library Prep Kits
- 8.3.1. Rna Library Prep
- 8.3.1.1. Mrna Kits
- 8.3.1.2. Small Rna Kits
- 8.3.1.3. Total Rna Kits
- 8.3.2. Targeted Library Prep
- 8.3.2.1. Inherited Disease Panels
- 8.3.2.2. Oncology Panels
- 8.3.3. Whole Genome Library Prep
- 8.3.3.1. Pcr-free Kits
- 8.3.3.2. Standard Wgs Kits
- 8.4. Target Enrichment Kits
- 8.4.1. Amplicon Enrichment
- 8.4.1.1. Multiplex Pcr
- 8.4.1.2. Singleplex Pcr
- 8.4.2. Hybridization Capture
- 8.4.2.1. Array Based
- 8.4.2.2. Solution Based
- 9. NGS Sample Preparation Market, by Technology
- 9.1. Bead Based
- 9.1.1. Magnetic Beads
- 9.1.2. Solid Phase Beads
- 9.2. Enzyme Based
- 9.2.1. Ligase
- 9.2.2. Restriction Enzyme
- 9.2.3. Transposase
- 9.3. Microfluidics
- 9.3.1. Droplet Based
- 9.3.2. Lab On Chip
- 9.4. Pcr Based
- 9.4.1. Conventional Pcr
- 9.4.2. Digital Pcr
- 9.4.3. Qpcr
- 10. NGS Sample Preparation Market, by Workflow Step
- 10.1. Amplification
- 10.1.1. Pcr Amplification
- 10.1.2. Rolling Circle
- 10.2. Enrichment
- 10.2.1. Amplicon
- 10.2.2. Hybridization
- 10.3. Fragmentation
- 10.3.1. Enzymatic
- 10.3.2. Mechanical
- 10.4. Library Preparation
- 10.4.1. Rna Prep
- 10.4.2. Targeted Prep
- 10.4.3. Wgs Prep
- 10.5. Quantification And QC
- 10.5.1. Electrophoretic
- 10.5.2. Fluorometric
- 11. NGS Sample Preparation Market, by Application
- 11.1. Epigenetics
- 11.1.1. Bisulfite Sequencing
- 11.1.2. Chip Sequencing
- 11.2. Metagenomics
- 11.2.1. 16s Rrna Sequencing
- 11.2.2. Shotgun Metagenomics
- 11.3. Rna Sequencing
- 11.3.1. Mirna Sequencing
- 11.3.2. Mrna Sequencing
- 11.3.3. Total Rna Sequencing
- 11.4. Targeted Sequencing
- 11.4.1. Inherited Disease
- 11.4.2. Oncology
- 11.4.3. Pharmacogenomics
- 11.5. Whole Genome Sequencing
- 12. NGS Sample Preparation Market, by End User
- 12.1. Academic And Government
- 12.2. Contract Research Organizations
- 12.3. Diagnostic Laboratories
- 12.4. Pharma And Biotech
- 13. NGS Sample Preparation Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. NGS Sample Preparation Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. NGS Sample Preparation Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Agilent Technologies, Inc.
- 16.3.2. Applied Biological Materials Inc.
- 16.3.3. Beckman Coulter by Danaher Corporation
- 16.3.4. BGI Group
- 16.3.5. Bio-Rad Laboratories, Inc.
- 16.3.6. Eppendorf SE
- 16.3.7. Eurofins Genomics LLC
- 16.3.8. F. Hoffmann-La Roche Ltd.
- 16.3.9. Illumina, Inc.
- 16.3.10. Integrated DNA Technologies, Inc.
- 16.3.11. Macrogen Inc.
- 16.3.12. Merck KGaA
- 16.3.13. New England Biolabs, Inc.
- 16.3.14. Novogene Co., Ltd.
- 16.3.15. PerkinElmer Inc.
- 16.3.16. Promega Corporation
- 16.3.17. Psomagen, Inc.
- 16.3.18. Qiagen N.V.
- 16.3.19. Sysmex Corporation
- 16.3.20. Takara Bio Inc.
- 16.3.21. Thermo Fisher Scientific Inc.
- 16.3.22. Zymo Research Corporation
- 16.3.23. FORMULATRIX, Inc.
- 16.3.24. Aurora Biomed Inc.
- 16.3.25. Standard BioTools Inc.
- 16.3.26. BioDynami
- 16.3.27. MCLAB
- 16.3.28. Magen Biotechnology Co., Ltd.
- 16.3.29. Oxford Nanopore Technologies PLC
- 16.3.30. Twist Bioscience Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
